Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¹æ¾Ï ¼ö¼ú ÈÄ ¾×¿Í¸²ÇÁÀý Àç¹ß Áø´Ü¿¡ À־ÀÇ ¹Ì¼¼Ä§¼¼Ã´¾× CYFRA 21-1ÀÇ Áø´ÜÀû °¡Ä¡ Diagnostic Value of CYFRA 21-1 Measurement in Fine-Needle Aspiration Washouts for Detection of Axillary Recurrence in Postoperative Breast Cancer Patients

´ëÇÑ¿µ»óÀÇÇÐȸÁö 2020³â 81±Ç 1È£ p.147 ~ 156
¿ø¼Ò¿¬, ±èÀº°æ, ¹®ÈñÁ¤, À±Á¤Çö, ¹Ú¿µÁø, ±è¹ÎÁ¤,
¼Ò¼Ó »ó¼¼Á¤º¸
¿ø¼Ò¿¬ ( Won So-Yeon ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼¼ºê¶õ½ºº´¿ø ¿µ»óÀÇÇаú

±èÀº°æ ( Kim Eun-Kyung ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼¼ºê¶õ½ºº´¿ø ¿µ»óÀÇÇаú
¹®ÈñÁ¤ ( Moon Hee-Jung ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼¼ºê¶õ½ºº´¿ø ¿µ»óÀÇÇаú
À±Á¤Çö ( Yoon Jung-Hyun ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼¼ºê¶õ½ºº´¿ø ¿µ»óÀÇÇаú
¹Ú¿µÁø ( Park Young-Jean ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼¼ºê¶õ½ºº´¿ø ¿µ»óÀÇÇаú
±è¹ÎÁ¤ ( Kim Min-Jung ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼¼ºê¶õ½ºº´¿ø ¿µ»óÀÇÇаú

Abstract

¸ñÀû: ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº À¯¹æ¾ÏÀ¸·Î ¼ö¼úÇÑ È¯ÀÚ¿¡¼­ ¸²ÇÁÀý Àç¹ßÀ» Áø´ÜÇÔ¿¡ ÀÖ¾î ¹Ì¼¼Ä§ÈíÀμ¼Ã´¾× cytokeratin fragment 21-1 (ÀÌÇÏ CYFRA 21-1) ÃøÁ¤ÀÇ Áø´ÜÀû °¡Ä¡¿Í ÀûÀýÇÑ ¿ªÄ¡°ªÀ» Æò°¡ÇÏ´Â °ÍÀÌ´Ù.

´ë»ó°ú ¹æ¹ý: 64¸íÀÇ À¯¹æ¾Ï ¼ö¼úÀ» ¹ÞÀº ȯÀÚ¿¡¼­ Àç¹ßÀÌ ÀǽɵǴ ÃÑ 64°³ÀÇ ¸²ÇÁÀý¿¡ ´ëÇØ ¹Ì¼¼Ä§ÈíÀμ¼Æ÷°Ë»ç¿Í ¹Ì¼¼Ä§¼¼Ã´¾× CYFRA 21-1 °Ë»ç¸¦ ½ÃÇàÇÏ¿´´Ù. ÃÖÁ¾ Áø´ÜÀº fine-needle aspiration ¼¼Æ÷°Ë»ç ¹× 2³â ÀÌ»óÀÇ ÃßÀû°üÂû·Î ÇÏ¿´´Ù. Àç¹ß ¸²ÇÁÀý°ú ¾ç¼º ¸²ÇÁÀýÀÇ CYFRA 21-1ÀÇ ³óµµ¸¦ ºñ±³ÇÏ¿´´Ù. Áø´Ü¼öÇ൵¿Í ¿ªÄ¡°ªÀº ¼ö½Å±âÀÛµ¿Æ¯¼º°î¼±À» ÀÌ¿ëÇÏ¿© ±¸Çß´Ù.

°á°ú: ºñÁø´ÜÀû °á°ú¿Í »ó°ü¾øÀÌ, CYFRA 21-1ÀÇ Áß°£ ³óµµ´Â ¾ç¼º ¸²ÇÁÀýº¸´Ù Àç¹ß ¸²ÇÁÀý¿¡¼­ À¯ÀÇÇÏ°Ô ³ô¾Ò´Ù(p < 0.001). ÀûÀýÇÑ ¿ªÄ¡°ªÀº 1.6 ng/mL¿´´Ù. ¸²ÇÁÀý Àç¹ß¿¡ ´ëÇÑ CYFRA 21-1ÀÇ ¹Î°¨µµ, ƯÀ̵µ, ¾ç¼º¿¹Ãøµµ, À½¼º¿¹Ãøµµ ¹× Á¤È®µµ´Â °¢°¢ 90.9%, 100%, 100%, 98.1%, 98.4%¿´´Ù.

°á·Ð: ¹Ì¼¼Ä§¼¼Ã´¾×¿¡¼­ CYFRA 21-1 ³óµµ ÃøÁ¤Àº ¿ªÄ¡°ªÀ» 1.6À¸·Î ÇÏ¿´À» ¶§ ¿ì¼öÇÑ Áø´Ü¼öÇ൵¸¦ º¸¿©ÁÖ¾ú´Ù. ÀÌ °á°ú´Â ¹Ì¼¼Ä§¼¼Ã´¾× CYFRA 21-1 ³óµµ ÃøÁ¤ÀÌ À¯¹æ¾Ï ¼ö¼ú ȯÀÚ¿¡¼­ ¾×¿Í¸²ÇÁÀý Àç¹ßÀ» Áø´ÜÇϴµ¥ ÀÖ¾î À¯¿ëÇÔÀ» º¸¿©ÁØ´Ù.

Purpose: The objective of this study was to evaluate the diagnostic value and threshold levels of cytokeratin fragment 21-1 (CYFRA 21-1) in fine-needle aspiration (FNA) washouts for detection of lymph node (LN) recurrence in postoperative breast cancer patients.

Materials and Methods: FNA cytological assessments and CYFRA 21-1 measurement in FNA washouts were performed for 64 axillary LNs suspicious for recurrence in 64 post-operative breast cancer patients. Final diagnosis was made on the basis of FNA cytology and follow-up data over at least 2 years. The concentration of CYFRA 21-1 was compared between recurrent LNs and benign LNs. Diagnostic performance and cut-off value were evaluated using a receiver operating characteristic curve.

Results: Regardless of the non-diagnostic results, the median concentration of CYFRA 21-1 in recurrent LNs was significantly higher than that in benign LNs (p < 0.001). The optimal diagnostic cut-off value was 1.6 ng/mL. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of CYFRA 21-1 for LN recurrence were 90.9%, 100%, 100%, 98.1%, and 98.4%, respectively.

Conclusion: Measurement of CYFRA 21-1 concentration from ultrasound-guided FNA biopsy aspirates showed excellent diagnostic performance with a cut-off value of 1.6 ng/mL. These results indicate that measurement of CYFRA 21-1 concentration in FNA washouts is useful for the diagnosis of axillary LN recurrence in post-operative breast cancer patients.

Å°¿öµå

Antigen CYFRA21.1; Postoperative Period; Lymph Nodes, Pathology; Recurrence; Biopsy, Fine-Needle

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS